305 related articles for article (PubMed ID: 29267399)
1. Novel mechanisms to inhibit HIV reservoir seeding using Jak inhibitors.
Gavegnano C; Brehm JH; Dupuy FP; Talla A; Ribeiro SP; Kulpa DA; Cameron C; Santos S; Hurwitz SJ; Marconi VC; Routy JP; Sabbagh L; Schinazi RF; Sékaly RP
PLoS Pathog; 2017 Dec; 13(12):e1006740. PubMed ID: 29267399
[TBL] [Abstract][Full Text] [Related]
2. The Effect of JAK1/2 Inhibitors on HIV Reservoir Using Primary Lymphoid Cell Model of HIV Latency.
de Armas LR; Gavegnano C; Pallikkuth S; Rinaldi S; Pan L; Battivelli E; Verdin E; Younis RT; Pahwa R; Williams SL; Schinazi RF; Pahwa S
Front Immunol; 2021; 12():720697. PubMed ID: 34531866
[TBL] [Abstract][Full Text] [Related]
3. Ruxolitinib and tofacitinib are potent and selective inhibitors of HIV-1 replication and virus reactivation in vitro.
Gavegnano C; Detorio M; Montero C; Bosque A; Planelles V; Schinazi RF
Antimicrob Agents Chemother; 2014; 58(4):1977-86. PubMed ID: 24419350
[TBL] [Abstract][Full Text] [Related]
4. Janus kinase inhibition suppresses PKC-induced cytokine release without affecting HIV-1 latency reversal ex vivo.
Spivak AM; Larragoite ET; Coletti ML; Macedo AB; Martins LJ; Bosque A; Planelles V
Retrovirology; 2016 Dec; 13(1):88. PubMed ID: 27998278
[TBL] [Abstract][Full Text] [Related]
5. JAK-STAT Signaling Pathways and Inhibitors Affect Reversion of Envelope-Mutated HIV-1.
Quan Y; Xu H; Han Y; Mesplède T; Wainberg MA
J Virol; 2017 May; 91(9):. PubMed ID: 28202754
[TBL] [Abstract][Full Text] [Related]
6. In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection.
Tsai P; Wu G; Baker CE; Thayer WO; Spagnuolo RA; Sanchez R; Barrett S; Howell B; Margolis D; Hazuda DJ; Archin NM; Garcia JV
Retrovirology; 2016 May; 13(1):36. PubMed ID: 27206407
[TBL] [Abstract][Full Text] [Related]
7. HIV DNA subspecies persist in both activated and resting memory CD4+ T cells during antiretroviral therapy.
Murray JM; Zaunders JJ; McBride KL; Xu Y; Bailey M; Suzuki K; Cooper DA; Emery S; Kelleher AD; Koelsch KK;
J Virol; 2014 Mar; 88(6):3516-26. PubMed ID: 24403590
[TBL] [Abstract][Full Text] [Related]
8. Repurposing BCL-2 and Jak 1/2 inhibitors: Cure and treatment of HIV-1 and other viral infections.
Reece MD; Song C; Hancock SC; Pereira Ribeiro S; Kulpa DA; Gavegnano C
Front Immunol; 2022; 13():1033672. PubMed ID: 36569952
[TBL] [Abstract][Full Text] [Related]
9. The role of cytokines in the establishment, persistence and eradication of the HIV reservoir.
Vandergeeten C; Fromentin R; Chomont N
Cytokine Growth Factor Rev; 2012; 23(4-5):143-9. PubMed ID: 22743037
[TBL] [Abstract][Full Text] [Related]
10. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy.
Pierson T; McArthur J; Siliciano RF
Annu Rev Immunol; 2000; 18():665-708. PubMed ID: 10837072
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic Approaches to Eradicate Latent HIV-1 in Resting CD4+ T Cells.
Sluis-Cremer N
Curr Top Med Chem; 2016; 16(10):1191-7. PubMed ID: 26324046
[TBL] [Abstract][Full Text] [Related]
12. Baricitinib reverses HIV-associated neurocognitive disorders in a SCID mouse model and reservoir seeding in vitro.
Gavegnano C; Haile WB; Hurwitz S; Tao S; Jiang Y; Schinazi RF; Tyor WR
J Neuroinflammation; 2019 Sep; 16(1):182. PubMed ID: 31561750
[TBL] [Abstract][Full Text] [Related]
13. The tyrosine kinase inhibitor Dasatinib blocks in-vitro HIV-1 production by primary CD4+ T cells from HIV-1 infected patients.
Pogliaghi M; Papagno L; Lambert S; Calin R; Calvez V; Katlama C; Autran B
AIDS; 2014 Jan; 28(2):278-81. PubMed ID: 24361684
[TBL] [Abstract][Full Text] [Related]
14. Expression and reactivation of HIV in a chemokine induced model of HIV latency in primary resting CD4+ T cells.
Saleh S; Wightman F; Ramanayake S; Alexander M; Kumar N; Khoury G; Pereira C; Purcell D; Cameron PU; Lewin SR
Retrovirology; 2011 Oct; 8():80. PubMed ID: 21992606
[TBL] [Abstract][Full Text] [Related]
15. Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in pediatric patients with extensive antiretroviral exposure.
Ruff CT; Ray SC; Kwon P; Zinn R; Pendleton A; Hutton N; Ashworth R; Gange S; Quinn TC; Siliciano RF; Persaud D
J Virol; 2002 Sep; 76(18):9481-92. PubMed ID: 12186930
[TBL] [Abstract][Full Text] [Related]
16. The Janus kinase inhibitor ruxolitinib reduces HIV replication in human macrophages and ameliorates HIV encephalitis in a murine model.
Haile WB; Gavegnano C; Tao S; Jiang Y; Schinazi RF; Tyor WR
Neurobiol Dis; 2016 Aug; 92(Pt B):137-43. PubMed ID: 26851503
[TBL] [Abstract][Full Text] [Related]
17. Stimulating the RIG-I pathway to kill cells in the latent HIV reservoir following viral reactivation.
Li P; Kaiser P; Lampiris HW; Kim P; Yukl SA; Havlir DV; Greene WC; Wong JK
Nat Med; 2016 Jul; 22(7):807-11. PubMed ID: 27294875
[TBL] [Abstract][Full Text] [Related]
18. Effect of histone deacetylase inhibitors on HIV production in latently infected, resting CD4(+) T cells from infected individuals receiving effective antiretroviral therapy.
Blazkova J; Chun TW; Belay BW; Murray D; Justement JS; Funk EK; Nelson A; Hallahan CW; Moir S; Wender PA; Fauci AS
J Infect Dis; 2012 Sep; 206(5):765-9. PubMed ID: 22732922
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibition reduces deleterious cytokine release induced by ingenol stimulation.
Larragoite ET; Nell RA; Martins LJ; Barrows LR; Planelles V; Spivak AM
Biochem Pharmacol; 2022 Jan; 195():114844. PubMed ID: 34801521
[TBL] [Abstract][Full Text] [Related]
20. Polyamides reveal a role for repression in latency within resting T cells of HIV-infected donors.
Ylisastigui L; Coull JJ; Rucker VC; Melander C; Bosch RJ; Brodie SJ; Corey L; Sodora DL; Dervan PB; Margolis DM
J Infect Dis; 2004 Oct; 190(8):1429-37. PubMed ID: 15378435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
